The data analytics firm EvaluatePharma compiled the forecasts based on pharmaceutical companies’ sales projections as of December 2023. Humira, AbbVie’s best-selling anti-inflammatory drug, is notably absent from the list, as the drug lost its market exclusivity in 2023.
Here are the 10 projected best-selling drugs in 2024 and their expected global sales:
1. Keytruda (Merck) — $27.2 billion
2. Ozempic (Novo Nordisk) — $16.1 billion
3. Dupixent (Sanofi) — $13.5 billion
4. Eliquis (Bristol Myers Squibb) — $13.3 billion
5. Biktarvy (Gilead) — $12.6 billion
6. Darzalex (Johnson & Johnson) — $12 billion
7. Opdivo (Bristol Myers Squibb/Ono Pharmaceutical) — $11.3 billion
8. Comimaty (Pfizer/BioNTech) — $10.8 billion
9. Gardasil (Merck/CSL) — $10 billion
10. Skyrizi (AbbVie) — $9.9 billion
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
